Journal Article

SIGNET: protocol for a multicentre, single-blind prospective, group sequential, randomised controlled trial to evaluate the benefits of a single dose of simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients

Thomas, Helen, Banks, Jennifer, McAuley, Daniel Francis, Shaw, James, Fisher, Andrew, MacGowan, Guy A, Evans, Amy, Watson, Christopher JE, Hodge, Renate, Yates, Hilary, Fallow, Andrea, Kounali, Daphne, Lawson, Emma, Keen, Katie, Stevens, Margaret, Harvey, Dan, Dark, John, Sheerin, Neil S, Mawson, Phil, Paul, Roshni

2024

Overview

IntroductionSuccessful organ transplantation in patients with end-stage organ failure improves long-term survival, improves quality of life and reduces costs to the NHS. Despite an increase in the number of deceased organ donors over the last decade, there remains a considerable shortfall of suitable organs available for transplantation. Over half of UK donors are certified dead by neurological criteria following brain stem compression, which leads to severe physiological stress in the donor, combined with a hyperinflammatory state. Brain stem death-related dysfunction is an important reason for poor organ function and hence utilisation. For example, more than 30% of donation after brain stem death cardiac transplant recipients need short-term mechanical cardiac support, reflecting donor heart dysfunction.A small, randomised study previously showed improved outcomes for cardiac transplant recipients if the donor was given simvastatin. SIGNET takes inspiration from that study and hypothesises a potential reduction in damage to the heart and other organs during the period after diagnosis of death and prior to organ retrieval in donors that receive simvastatin.Methods and analysisSIGNET is a multicentre, single-blind, prospective, group sequential, randomised controlled trial to evaluate the benefits of a single high dose of simvastatin given to potential organ donors diagnosed dead by neurological criteria on outcomes in all organ recipients. The trial will run across a minimum of 89 UK sites with a recruitment target of 2600 donors over 4 years.Ethics and disseminationSIGNET received a favourable opinion from the London, Queen Square Research Ethics Committee (Ref: 21/LO/0412) and following approval of substantial amendment 1 in January 2023, the current protocol is version 2 (7 December 2022). Substantial amendment 1 clarified consent procedures and added additional sites and prescribers. Findings from the study will be publicly available and disseminated locally and internationally through manuscript publications in peer-reviewed journals and conference presentations at national and international platforms.Trial registration numberISRCTN11440354

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Blood & organ donations / Brain Death / Brain research / Clinical outcomes / Consent / Heart transplants / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage / Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use / INTENSIVE & CRITICAL CARE / Intensive Care / Liver / Mortality / Multicenter Studies as Topic / Organ Transplantation / Patients / Prospective Studies / Protocol / Quality of life / Randomized Controlled Trial / Randomized Controlled Trials as Topic / Simvastatin - administration & dosage / Simvastatin - therapeutic use / Single-Blind Method / Tissue Donors / TRANSPLANT MEDICINE / United Kingdom